GlobeNewswire: Cytokinetics, Incorporated Contains the last 10 of 426 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T19:48:07ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/25/2851599/0/en/Cytokinetics-Announces-Four-Upcoming-Presentations-at-the-American-College-of-Cardiology-73rd-Annual-Scientific-Session.html?f=22&fvtc=4&fvtv=25813Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session2024-03-25T12:15:04Z<![CDATA[SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American College of Cardiology 73rd Annual Scientific Session (ACC.24) taking place in Atlanta, GA from April 6, 2024 – April 8, 2024.]]>https://www.globenewswire.com/news-release/2024/03/04/2839946/0/en/Cytokinetics-to-Participate-in-March-Investor-Conferences.html?f=22&fvtc=4&fvtv=25813Cytokinetics to Participate in March Investor Conferences2024-03-04T21:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in March:]]>https://www.globenewswire.com/news-release/2024/03/01/2839053/0/en/Cytokinetics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=25813Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2024-03-01T21:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 29, 2024 it granted stock options to purchase an aggregate of 28,500 shares of common stock to three new employees, whose employment commenced in February 2024, as a material inducement to their employment.]]>https://www.globenewswire.com/news-release/2024/02/29/2837869/0/en/Cytokinetics-Joins-Global-Initiative-to-Recognize-International-Rare-Disease-Day.html?f=22&fvtc=4&fvtv=25813Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day2024-02-29T12:30:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is joining the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) to recognize Rare Disease Day®. Rare Disease Day® is an international campaign elevating the awareness and public understanding of rare diseases. The initiative spotlights the more than 300 million people worldwide living with a rare disease, and the awareness efforts focused on bringing them more equitable access to diagnosis, treatment, care and social opportunity.]]>https://www.globenewswire.com/news-release/2024/02/28/2836860/0/en/Cytokinetics-The-Mended-Hearts-Inc-and-WomenHeart-Announce-Launch-of-New-Initiative-to-Increase-Engagement-in-Cardiovascular-Clinical-Trials.html?f=22&fvtc=4&fvtv=25813Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase Engagement in Cardiovascular Clinical Trials2024-02-28T12:30:00Z<![CDATA[Grant Funding Provided by Cytokinetics to Each Organization to Help Increase Clinical Trial Engagement Among Historically Underrepresented Groups Grant Funding Provided by Cytokinetics to Each Organization to Help Increase Clinical Trial Engagement Among Historically Underrepresented Groups]]>https://www.globenewswire.com/news-release/2024/02/27/2836411/0/en/Cytokinetics-Reports-Fourth-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=25813Cytokinetics Reports Fourth Quarter 2023 Financial Results2024-02-27T21:00:00Z<![CDATA[Topline Results from SEQUOIA-HCM Announced in DecemberShowed Statistically Significant and Clinically Meaningful Increasein Primary Efficacy Endpoint and Improvements in All Secondary Endpoints]]>https://www.globenewswire.com/news-release/2024/02/13/2828620/0/en/Cytokinetics-to-Announce-Fourth-Quarter-Results-on-February-27-2024.html?f=22&fvtc=4&fvtv=25813Cytokinetics to Announce Fourth Quarter Results on February 27, 20242024-02-13T21:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 27, 2024 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future.]]>https://www.globenewswire.com/news-release/2024/02/06/2824697/0/en/Cytokinetics-to-Participate-in-the-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html?f=22&fvtc=4&fvtv=25813Cytokinetics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference2024-02-06T21:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 10:40 AM Eastern Time.]]>https://www.globenewswire.com/news-release/2024/01/29/2818792/0/en/Cytokinetics-Announces-Recipients-of-Its-Sixth-Annual-Communications-Grant-Program.html?f=22&fvtc=4&fvtv=25813Cytokinetics Announces Recipients of Its Sixth Annual Communications Grant Program2024-01-29T12:30:00Z<![CDATA[Total of $100,000 Awarded to Five Patient Advocacy Organizations to Support Communications and Community Outreach Total of $100,000 Awarded to Five Patient Advocacy Organizations to Support Communications and Community Outreach]]>https://www.globenewswire.com/news-release/2024/01/25/2816620/0/en/Cytokinetics-Presents-New-Data-at-CMR-2024-From-FOREST-HCM-the-Open-Label-Extension-Clinical-Trial-of-Aficamten.html?f=22&fvtc=4&fvtv=25813Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten2024-01-25T12:30:00Z<![CDATA[New Data Show Treatment with Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy Resulted in Favorable Structural Remodeling, Improvements in Cardiac Function and Stabilization of Fibrosis New Data Show Treatment with Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy Resulted in Favorable Structural Remodeling, Improvements in Cardiac Function and Stabilization of Fibrosis]]>